Specialty Pharmacy

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

Targeted therapy for sleep disorders more effective in patients with muscular dystrophy.

The majority of HIV-positive individuals 50 years or older live on or below the poverty line.

Kalytera will acquire Talent Biotechs phase 2 trial of cannabidiol in graft versus host disease.

Level of emotional distress after prostate cancer diagnosis increases likelihood of choosing surgery over active surveillance.

Top news of the day from across the health care landscape.

Providers need to monitor lack of physical activity and poor diet among patients with multiple sclerosis.

Top news of the week on Specialty Pharmacy Times.

Cancer cells more prone to damage and death from high amounts of hydrogen peroxide.

Dementia is one of the most prevalent complications among patients with late-stage HIV.

Antiretrovirals may increase vulnerability to syphilis in males with HIV.

Marc O'Connor, CEO and chief strategy officer of Curant Health, discusses how projected drug spending growth will alter the specialty pharmacy landscape in the future.

Study provides better understanding of why some cancers are resistant to therapy.

Prickly pear and brown seaweed extracts provide hope for age-related diseases.

The diabetic effects on surgical outcomes found to be overstated.

Symptoms significantly worsened in patients treated with MS drug alemtuzumab.

Top news of the day from across the health care landscape.

FDA approves first generic version of Xyrem (sodium oxybate) Oral Solution for the treatment of cataplexy and daytime sleepiness in patient with narcolepsy.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Agency releases guidelines to determine the interchangeability of biosimilars with their reference products.

Guidance intends to help sponsors demonstrate Interchangeability with a reference product.

Real-time reporting of patient symptoms has shown proven health benefits.

Individuals enrolled in high-deductible health plans face thousands in out of pocket costs.

Histone H3 protein is abnormal or incorrectly modified in 15% of patients with head and neck cancer.

Study confirms safety and efficacy of Lu-177-PSMA-17 radioligand therapy for metastatic castration-resistant prostate cancer.

South African Pharmacy Council lifts ban preventing pharmacies from selling DIY HIV test kits.

CanChew Plus CBD gum may eventually treat irritable bowel disease, Crohn’s disease, and ulcerative colitis.

Top news of the day from across the health care landscape.

Sale of Panretin gel tubes approved in the United States due to a drug shortage as a result of a manufacturing issue.